Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.
You may also be interested in...
The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
Immunovaccine’s investigational cancer vaccine combined with an immunomodulator and a checkpoint inhibitor or other similar type of agent could have a synergistic beneficial effect on tumor cells, and lead to triple-drug combinations being evaluated in other cancers.